All In Biotech

Drug Trial Radar · NCT04361552

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2: An Open-Labeled, Randomized Phase 3 Trial

Last checked: Nov 19, 2026Latest source record: Jun 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

WithdrawnPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Withdrawn

Enrollment

0

Actual

Start

Apr 7, 2020

Primary completion

Jun 2, 2020

Study completion Jun 2, 2020

Sponsor

Lead sponsor
Emory UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Apr 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.

Conditions

  • Cerebrovascular Accident
  • Chronic Obstructive Pulmonary Disease
  • Chronic Renal Failure
  • Coronary Artery Disease
  • Diabetes Mellitus
  • Malignant Neoplasm
  • SARS Coronavirus 2 Infection

Interventions

  • Best PracticeOther

    Receive standard of care

  • TocilizumabBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 7-day length of invasive mechanical ventilation (MV)Time frame: Up to 7 days
  2. 30-day mortality rateTime frame: Up to 30-day after randomization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.